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The treatment of acute myeloid leukemia (AML) isamong the most dose-intensive approaches in clini-cal oncology and involves variable therapeutic
options with highly diverse consequences in terms of toxi-
cities and anti-leukemic effects. One illustrative example is
the choice between consolidation chemotherapy and stem
cell transplantation in first remission and also the choice
among highly diverse types of stem cell transplantation
such as autologous, allogeneic-sibling, haplo-identical,
unrelated donor or umbilical cord blood grafting.
Prognostic factors provide guidance in clinical practice in
these complex treatment management dilemmas. An aver-
age 40% of adult patients up to the age of 60 will have
long-term survival prospects; for older patients this is only
10-15%. Among these estimates there is considerable vari-
ation in outcome between individual patients. Patient relat-
ed factors (e.g. age, comorbidity conditions) and hemato-
logic factors (e.g. ‘de novo’ vs. secondary AML) impact on
individual treatment outcome. Most prominently, particu-
lar leukemia-specific somatic genetic alterations furnish
essential prognostic determinants. These genomic abnor-
malities in the leukemic blasts are assessed with classical
cytogenetic techniques (banding, fluorescence in situ
hybridization) or a range of molecular methods. There is no
question that cytogenetics, more than any other genetic
source of information, has become solidly established in
the diagnostic work up of patients with AML.1-3
Cytogenetics unravels the highly variable clinical biology of
AML and thus allows for sharp clinically useful diagnostic
and prognostic distinctions. Recent studies have revealed
that AML with so called monosomal karyotypes are at the
extreme unfavorable end of the prognostic spectrum and
predict one of the worst possible outcomes. This issue of
the journal contains a report by Xie et al. that examined the
significance of residual karyotypically normal cells in
monosomal karyotype AML (MK-AML).4
Monosomal karyotype AML: what is it about?
During the past 25 years several large clinical trial
groups, such as the Dutch-Belgian Hemato-Oncology
Cooperative Group (HOVON) and the Swiss Group for
Clinical Cancer Research (SAKK), have collected cytoge-
netic diagnostics at baseline in patients with AML
enrolled in their treatment protocols. This has generated
data sets in large series of comparatively homogeneously
treated patients in whom the prognostic contribution of
various cytogenetic abnormalities such as complex kary-
otypes (i.e. multiple chromosomal aberrations) could be
evaluated. Statistical analysis revealed that loss of a com-
plete autosomal chromosome conferred profound nega-
tive prognostic impact (Figure 1A), whereas structural
abnormalities negatively influenced prognosis in associa-
tion with an autosomal monosomy.5 Extra chromosomes
Figure 1. Overall survival of patients with acute myeloid leukemia
(AML) and non-core-binding-factor chromosomal abnormalities. (A)
Survival in relation to numbers of autosomal chromosomal mono-
somies (none, 1, and ≥2 ms). (B) Survival in relation to ‘monosomal
karyotype’ (in figure designated as MI) as defined by Breems et al.5
and/or ‘complex karyotype with ≥3 cytogenetic clonal abnormali-
ties’ (CK). Reprinted with permission. „2008 American Society of
Clinical Oncology. All rights reserved.” Breems D et al. J Clin Oncol
2008;26(29):4791-7.
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(e.g. trisomies) had a minor effect on prognosis. Based on
these observations, the ‘monosomal karyotype’ as a pre-
dictor for very poor prognosis of AML was identified.
MK-AML, referring to at least two autosomal mono-
somies or a single autosomal monosomy plus an addi-
tional structural cytogenetic abnormality were, therefore,
postulated as a more homogeneous distinguishable sub-
set of AML representative with an extremely adverse out-
come.5 In direct comparisons, MK provided significantly
better prognostic prediction than the traditionally defined
complex karyotype that considers any 3 or more, 4 or
more, or 5 or more clonal cytogenetic abnormalities.5 As
a matter of fact, it also became apparent that complex
karyotype AML is by no means prognostically different
from any generally cytogenetically aberrant AML if kary-
otypes with deletions of complete chromosomes (mono-
somies) were excluded from the complex karyotypes
(Figue 1B).5 Thus, MK-AML, in addition to AML with
normal cytogenetics and core-binding-factor abnormali-
ties, represents a new distinct aggregate of cytogenetical-
ly abnormal AML (Figure 2).5
What do we currently know about monosomal 
karyotype AML?
It is notable that AML with complex karyotypes have
for long been accepted for their unfavorable prognosis
while only recently has it become clear that the unfavor-
able impact of the complex karyotypes is predominantly
due to the fact that they are heavily admixed with
monosomal karyotypes.5 In the original HOVON-SAKK
report, the MK-AML was prevalent in about 9% of AML
patients between 15 to 60 years of age.5 In subsequent
studies, MK-AML has been reported in about 6-10%
among patients with newly diagnosed AML although
the prevalence goes up with increasing age.6-9 For exam-
ple, Medeiros et al. reported a frequency of MK-AML of
about 20% in newly diagnosed patients with AML over
the age of 60 years8 (Table 1). AML with MK has poor
outcome in patients in any age group and even young
patients show a comparatively poor complete remission
(CR) rate and survival estimate when they present with
MK-AML.5 Subsequent studies have confirmed these
findings (Table 1). In the recent HOVON-SAKK studies,
the CR rates for MK-AML were no more than 52% in
patients between 18 to 60 years9 and only 34% in
patients with MK-AML older than 60 years.6 A study
from the South West Oncology Group (SWOG) reported
exceptionally low CR rates of only 50% in patients
under the age of 31 years, 27% in patients 31-40 years,
14% for patients 41-50 years, 24% for patients aged 51-
60 years and 13 % for patients with MK-AML aged over
60.8 In addition to CR rates, the survival estimates in
AML with MK are universally poor (Table 1). In the orig-
inal study for patients up to 60 years of age, the 4-year
overall survival (OS) was estimated at only 4%. These
highly unfavorable results have also been noted in sub-
sequent studies. The SWOG study reported an OS of
3% at four years8 and the HOVON-SAKK group in their
recent prospective studies reported 7% OS at five years
in patients under 60 years of age9 and 4% OS at two
years in patients over 60 years of age.6 In the SWOG
study, patients with AML between 41 to 88 years of age
showed an estimated survival of less than 1% at four
years8 and in the HOVON-SAKK study in patients 60
years and older there were no long-term survivors at five
years.6 The very poor prognosis of MK-AML was also
apparent in a large-scale study in more than 5,500
patients with AML in patients between 16 to 59 years of
age by the United Kingdom Medical Research Council
(10-year OS: 5%).7 Not only in AML, but also in patients
with high-risk myelodysplastic syndrome (MDS), the
presence of MK appears to confer a notably poor out-
come. An analysis of the Mayo Clinic database showed
that in adult MDS with complex karyotype the MK is
also a predictor for very unfavorable survival (2-year OS:
23% in MK- and 6% in MK+ MDS).10
In this issue of the journal, investigators report an
effort to identify prognostic heterogeneity among MK-
AML.4 They looked at the significance of residual nor-
mal karyotypes in 176 patients with MK in a multivari-
ate analysis. Previously, Estey et al. had reported in
another context that a subgroup of AML and MDS with
chromosome 5 and/or 7 abnormalities exhibit a some-
what more favorable prognosis when these abnormali-
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Table 1. Frequencies, complete remission rates and overall survival
estimates of newly diagnosed patients with acute myeloid leukemia
and monosomal karyotype in relationship to age.
Age Frequency*    Complete          Overall                Reference
             remission         survival
≤ 30 years nr                     nr             17% at 4 years           Breems et al.5
4%                   50%           40% at 4 years         Medeiros et al.8
≤ 60 years 9%                   48%            4% at 4 years            Breems et al.5
6%                     nr             5% at 10 years        Grimwade et al.7
10%                  24%            3% at 4 years          Medeiros et al.8
10%                  52%            7% at 5 years        Löwenberg et al.9
> 60 years 13%                  34%            4% at 2 years        Löwenberg et al.6
20%                  13%            1% at 4 years          Medeiros et al.8
nr: not reported. *indicates frequency of monosomal karyotype acute myeloid leukemia
among all patients.
Figure 2. Overall survival of four prognostic subcategories of acute
myeloid leukemia (AML) aggregated according to cytogenetics.
Core-binding-factor (CBF) abnormalities. Normal karyotype (CN).
Non-CBF abnormalities but 'monosomal karyotype' negative (in fig-
ure designated as MI-) and non-CBF abnormalities but 'monosomal
karyotype' positive (in figure designated as MI+). MK refers to ≥2
autosomal monosomies or one autosomal monosomy with at least
one structural abnormality. Breems D et al. J Clin Oncol 2008;
26(29):4791-7.
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ties are found in combination with more than one resid-
ual normal metaphase.11 In the study reported here, MK-
AML shows statistically a slightly better survival at two
years of follow up when normal metaphases are appar-
ent, although the survival of even those patients
remained very poor.4
Therapeutic implications of monosomal karyotype AML?
The excessively poor prognostic subgroup of AML with
MK is explained by resistance against current treatment
modalities resulting in a low CR percentage. CRs
achieved following 3+7 anthracyclin-cytarabine induction
chemotherapy in MK-AML are of poor quality which is
evident from the high and early relapse rate after CR.
This high relapse rate is also apparent in an analysis of the
University of Minnesota showing a relapse rate of 62% at
four years of patients with MK-AML who had been treat-
ed with an allogeneic stem cell transplantation in their
first CR.12 On the other hand, preliminary data from the
HOVON-SAKK cooperative group suggest that patients
submitted to an allogeneic stem cell transplantation have
a better prognosis than those submitted to chemotherapy
programs (HOVON-SAKK cooperative group, unpub-
lished results). Thus, an allogeneic stem cell transplanta-
tion, which is the currently recommended consolidation
treatment for poor-risk AML in general,13,14 also seems to
be the treatment of choice in patients with MK-AML as
one of few available treatment options. Meanwhile, novel
more active therapies are evidently badly needed for MK-
AML. This means that MK-AML represents a subtype of
AML that is heavily dependent on investigational explo-
rative approaches and particularly suitable for new drug
development even in front-line treatment situations.
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Success in the treatment of cancer has led to an expand-ing population of survivors with their attendant long-term complications. Treatment with cytotoxic, DNA-
interactive drugs and radiation is well known to predispose
to the development of secondary tumors, in particular sec-
ondary myelodysplasia and acute myeloid leukemia
(AML).1 Such therapy related neoplasms have been associ-
ated with recurring chromosomal abnormalities such as
translocations involving the MLL gene (commonly seen
within a few years after therapy with topoisomerase II
inhibitors) and loss of part or the whole of chromosomes 5
and 7 (frequently observed several years after treatment
with the alkylating agents).1 The occurrence of these recur-
ring chromosomal aberrations and their association with
specific chemotherapeutic agents is suggestive of a specific
interaction between these drugs and the genome.1
